| Literature DB >> 29198621 |
Daniele Corridoni1, Alison Simmons2.
Abstract
A critical role of pattern recognition receptors (PRRs) is to influence adaptive immune responses by regulating antigen presentation. Engagement of PRRs in dendritic cells (DCs) increases MHC class I antigen presentation and CD8+ T-cell activation by cross-presented peptides but the molecular mechanisms underlying these effects are not completely understood. Studies looking at the role of PRRs in cross-presentation have been largely limited to TLRs but the role of other PRRs such as cytosolic nucleotide-binding oligomerization domain-like (NOD-like) receptors remains particularly enigmatic. Here we discuss recent evidence of the role of PRRs on cross-presentation and consider how cytosolic NLR-associated pathways, such as NOD2, may integrate these signals resulting in effective adaptive CD8+ T cells responses. CrownEntities:
Keywords: CD8+ T cells; Cross-presentation; MHC class I; NLRs; PRRs
Mesh:
Substances:
Year: 2017 PMID: 29198621 PMCID: PMC6859786 DOI: 10.1016/j.molimm.2017.11.028
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407
Fig. 1NLR-dependent regulation of MHC class I antigen presentation. (A) NLRC5 induces chromatin remodeling and recruitment of transcription factors, leading to the transactivation of MHC class I, and other related genes in the MHC class I antigen-presentation pathway, including LMP2, LMP7, TAP1, and β2-microglobulin. (B) Activation of the NLRP3 inflammasome and its effector caspase-1 acts on the NADPH oxidase NOX2 to induce phagosome acidification in response to microbial infection. This process negatively impacts cross-presentation. (C) NOD1 and NOD2 activation by peptidoglycan (PGN) significantly augments DC-mediated cross-presentation via upregulation of intracellular components, such as TAP, SEC61, and calnexin, for MHC class I dependent antigen presentation and co-stimulatory molecules expression. In addition, early activation of NOD2 signaling alone or in combination with TLR2 may be required for stabilisation of the immunoproteasome and promote cross-presentation during an early phase of pathogen handling. (D) PGN pre-treatment, prior to antigen encounter, leads to progressive inhibition of cross-presentation over time, with almost complete inhibition after 18 h.